Welcome to our dedicated page for DFPH news (Ticker: DFPH), a resource for investors and traders seeking the latest updates and insights on DFPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DFPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DFPH's position in the market.
Dr. John Khoury of The Oncology Institute has been honored with the "40 Under 40 in Cancer" award for the second consecutive year, recognized by the Association for Value-Based Cancer Care. Dr. Khoury, a triple board-certified physician, emphasizes patient-centric care and is involved in clinical trials. The Oncology Institute is set to become publicly traded via a business combination with DFP Healthcare on November 12, 2021. This event is pivotal for both companies and aims to enhance their market position in oncology care.
DFP Healthcare Acquisitions Corp. (DFPH) has scheduled a special meeting of stockholders for November 12, 2021, at 10:00 a.m. ET, to approve a business combination with The Oncology Institute (TOI), a leader in value-based oncology care. The definitive proxy statement/prospectus has been filed and distributed to stockholders as of the September 23, 2021 record date. Approval of the transaction is pending stockholder consent and customary conditions, with closing expected soon after the meeting.
DFP Healthcare Acquisitions Corp (NASDAQ: DFPH, DFPHW) announced a definitive merger agreement with The Oncology Institute (TOI), a leader in value-based oncology care. This integration aims to disrupt the $200 billion U.S. oncology market, enhancing patient access to quality care and managing treatment costs. The transaction values the combined entity at roughly $842 million, with significant financial backing from top healthcare investors. Following the merger, DFP will be renamed TOI and expects an initial market cap of about $1.06 billion. The closing is anticipated in Q3 or Q4 of 2021.
